drugset / Trial / NCT02342145

Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major

NCT02342145

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the basiliximab for prevention of graft-versus-host disease in unrelated allo-genetic hematopoietic stem cell transplantation for thalassemia major. The objective was to evaluate the effect and safety of basiliximab for acute graft-versus-host disease.

Timeline

Start
2015-04
Primary completion
2022-08-20
Completion
2022-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Basiliximab Monoclonal antibody 10 mg
Subject Basiliximab Monoclonal antibody 20 mg
Background Methotrexate Small molecule 10 mg/m2 Intravenous
Background Mycophenolate Mofetil Small molecule 0.25 g
Background Tacrolimus Small molecule 0.1 mg/kg Intravenous